Search results for "Estrogen Receptor Status"

showing 8 items of 8 documents

Transforming Growth Factor Beta 1 Serum Levels in Patients with Preinvasive and Invasive Lesions of the Breast

2004

Transforming growth factor beta (TGF-beta)1 is thought to be involved in breast carcinogenesis. TGF-beta1 acts in an antiproliferative manner in the early stages of breast carcinogenesis, but promotes tumor progression and metastases in the advanced stages of the disease. No data have been published on serum TGF-beta1 in breast cancer. We investigated TGF-beta1 serum levels in patients with breast cancer (n=135), ductal carcinoma in situ (DCIS) I to III (n=67) or fibroadenoma (n=35), and in healthy women (n=40) to determine its value as a differentiation marker between malignant, pre-invasive and benign diseases and as a predictive marker for metastatic spread. Median (range) TGF-beta1 seru…

AdultOncology0301 basic medicinemedicine.medical_specialtyPathologyCancer ResearchMammary glandClinical BiochemistryCA 15-3Breast NeoplasmsPathology and Forensic MedicineTransforming Growth Factor beta103 medical and health sciencesBreast cancer0302 clinical medicineTransforming Growth Factor betaInternal medicinemedicineHumansNeoplasm Invasivenessskin and connective tissue diseasesEstrogen Receptor StatusAgedNeoplasm StagingAged 80 and overPredictive markerbusiness.industryMiddle AgedDuctal carcinomamedicine.diseaseFibroadenomamedicine.anatomical_structure030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisbusinessThe International Journal of Biological Markers
researchProduct

Imunohistochemical Demonstration of Carcinoembryonic Antigen (CEA) in 120 Mammary Carcinomas and its Correlation with Tumor Type, Grading, Staging Pl…

1985

Antisera to CEA were used for the immunohistochemical localization and quantification of this antigen in 120 Bouin-fixed, paraffin embedded mammary carcinomas. These results were compared to tumor type, grading, staging, biochemical receptor status, cytosolic CEA-levels of the same tumors, and preoperative plasma CEA-levels. Mammary carcinomas were usually characterized by a low percentage of CEA-positive tumor cells: 50.9% of the cases contained more than 5% CEA-positive tumor cells and were therefore defined as being CEA-histopositive in this study. A relation could be shown between CEA-histopositivity and the histologic tumor type. The majority of invasive lobular carcinomas, tubular, an…

AdultPathologymedicine.medical_specialtyReceptor Statusendocrine system diseasesBreast NeoplasmsPathology and Forensic MedicineImmunoenzyme TechniquesCarcinoembryonic antigenAntigenAntigens NeoplasmmedicineCarcinomaHumansneoplasmsEstrogen Receptor StatusGrading (tumors)Agedbiologybusiness.industryCarcinomaCell BiologyMiddle Agedmedicine.diseasedigestive system diseasesCarcinoembryonic AntigenCarcinoma Intraductal NoninfiltratingReceptors EstrogenInvasive lobular carcinomabiology.proteinImmunohistochemistryFemalebusinessPathology - Research and Practice
researchProduct

Coordinates in the Universe of Node-Negative Breast Cancer Revisited

2009

Abstract We present a global picture of the natural history of node-negative breast cancer in which two of three important biological processes have outstanding prognostic consequences. We propose that the transition from slow to fast proliferation of the tumor leads to the most dramatic aggravation of prognosis. Second, immune cell infiltration is of major importance to prevent disease progression in fast-proliferating breast carcinomas, regardless of estrogen receptor status. In the absence of endocrine treatment, steroid hormone receptor expression as a third axis is of limited prognostic importance. Dissecting tumors according to these three major biological axes will allow further unde…

CA15-3Cancer ResearchPathologymedicine.medical_specialtySteroid hormone receptorbusiness.industryCancerBreast Neoplasmsmedicine.diseaseBreast cancerOncologyTumor progressionLymphatic MetastasismedicineCancer researchHumansEndocrine systemFemaleLymph NodesBreast diseasebusinessEstrogen Receptor StatusCancer Research
researchProduct

3H-estradiol and3H-R5020 binding in cytosols of normal and neoplastic human ovarian tissue

1983

High-affinity cytoplasmic estrogen and progesterone receptors in normal and abnormal ovarian tissues were studied. Estradiol receptor was detectable in 65% and progesterone receptor in 36% of the malignant tumors; 39% of all malignant ovarian tissues were estradiol- as well as progesterone-receptor-positive. Tumors were said to be receptor-positive when the receptors bound greater than 5 fM steroid/mg cytosol protein. No correlations were found between receptor status and histopathological diagnosis. In normal ovarian tissues collected at various phases of the menstrual cycle no changes in [3H]-estradiol and [3H]-R5020 binding could be detected. Analysis of the receptor concentration for bo…

Cancer Researchmedicine.medical_specialtyReceptor StatusNorpregnadienesmedicine.drug_classmedia_common.quotation_subjectOvaryReceptors EstradiolBiologyTritiumPromegestoneCytosolOvarian carcinomaInternal medicineProgesterone receptormedicineHumansEstrogen Receptor StatusMenstrual cyclemedia_commonOvarian NeoplasmsTranscortinEstradiolOvaryEndocrinologymedicine.anatomical_structureReceptors EstrogenOncologyEstrogenFemaleReceptors Progesteronehormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugInternational Journal of Cancer
researchProduct

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2…

2012

Abstract Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers should allow further tumor characterization. Methods: We used data from 4,325 BRCA1 and 2,568 BRCA2 mutation carriers to analyze the pathology of invasive breast, ovarian, and contralateral breast cancers. Results: There was strong evidence that the proportion of estrogen receptor (ER)-negative breast tumors decreased with age at diagnosis among BRCA1 (P-trend = 1.2 × 10−5), but increased with age at diagnosis among BRCA2, carriers (P-trend = 6.8 × 10−6). The proportion of triple-negative tumors decreased with age at diagnos…

OncologyPathologyendocrine system diseasesEpidemiologyGenes BRCA2Genes BRCA1Estrogen receptorGene mutation0302 clinical medicineCancer screeningMedicineskin and connective tissue diseasesEstrogen Receptor StatusOvarian Neoplasms0303 health sciencesMiddle Agedfemale genital diseases and pregnancy complications3. Good healthSerous fluidtriple-negative tumorsOncology030220 oncology & carcinogenesisFemaleestrogen receptorAdultmedicine.medical_specialtyBRCA1; BRCA2; breast cancer; estrogen receptor; triple-negative tumorsHereditary cancer and cancer-related syndromes Genetics and epigenetic pathways of disease [ONCOL 1]Breast NeoplasmsArticle03 medical and health sciencesbreast cancerBreast cancerSDG 3 - Good Health and Well-beingTranslational research [ONCOL 3]Internal medicineHumansGenetic Predisposition to DiseaseGenetics and epigenetic pathways of disease Translational research [NCMLS 6]Germ-Line MutationAged030304 developmental biologyHereditary cancer and cancer-related syndromes [ONCOL 1]business.industryCancerBRCA1medicine.diseaseBRCA2Neoplasm GradingbusinessOvarian cancer
researchProduct

Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk

2019

Breast cancer in men is a rare and still poorly characterized disease. Inherited mutations in BRCA1, BRCA2 and PALB2 genes, as well as common polymorphisms, play a role in male breast cancer genetic predisposition. Male breast cancer is considered a hormone-dependent tumor specifically related to hyperestrogenism. Polymorphisms in genes involved in estrogen biosynthesis and metabolism pathways, such as CYP17A1 and CYP1B1, have been associated with breast cancer risk. Here, we aimed to investigate the role of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. A series of 597 male breast cancer cases and 1022 male controls, recruited within the Italian Multicenter Study on male brea…

Oncologymedicine.medical_specialtyEndocrinology Diabetes and MetabolismPALB2Diseasemale breast cancerHyperestrogenismlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineEndocrinologyBreast cancerInternal medicineGenotypeCYP17A1Internal MedicineGenetic predispositionMedicine030212 general & internal medicineskin and connective tissue diseasesEstrogen Receptor Statusmale breast cancer; CYP17A1; CYP1B1; polymorphisms; male breast cancer risklcsh:RC648-665business.industryResearchmedicine.diseasemale breast cancer risk030220 oncology & carcinogenesisMale breast cancerCYP1B1medicine.symptombusinesspolymorphismsEndocrine Connections
researchProduct

C-myc mRNA Expression in Epithelial Ovarian Carcinomas in Relation to Estrogen Receptor Status, Metastatic Spread, Survival Time, FIGO Stage, and His…

1998

Recently, it has been suggested that c-myc expression might correlate with estrogen receptor (ER) status and metastatic spread in ovarian cancer. In this study, expression of c-myc mRNA in 90 epithelial ovarian carcinomas was determined using the S1 nuclease protection assay. Expression of c-myc mRNA was detectable in 27 of 90 tumors. There was no significant association between c-myc mRNA expression and metastatic spread, survival time, FIGO stage, or histologic grade and type. C-myc mRNA was expressed in 45% of ER-positive tumors but only 24% of ER-negative tumors (p = 0.094; Fisher's exact test). Similarly, 44% of progesterone receptor (PR)-positive and 23% of PR-negative tumors expresse…

Pathologymedicine.medical_specialtymedicine.drug_class10050 Institute of Pharmacology and ToxicologyEstrogen receptor610 Medicine & healthOvaryBiologyPathology and Forensic MedicineMetastasisProto-Oncogene Proteins c-mycProgesterone receptormedicineHumansRNA MessengerRNA NeoplasmSurvival rateEstrogen Receptor StatusOvarian NeoplasmsCarcinomaObstetrics and Gynecology2729 Obstetrics and Gynecologymedicine.diseaseSurvival Rate2734 Pathology and Forensic Medicinemedicine.anatomical_structureReceptors EstrogenEstrogen570 Life sciences; biologyFemaleReceptors ProgesteroneOvarian cancerInternational Journal of Gynecological Pathology
researchProduct

Sex steroids, carcinogenesis, and cancer progression

2004

The relationship between sex steroids and cancer has been studied for more than a century. Using an original intact cell analysis, we investigated sex steroid metabolism in a panel of human cancer cell lines, either hormone responsive or unresponsive, originating from human breast, endometrium, and prostate. We found that highly divergent patterns of steroid metabolism exist and that the catalytic preference (predominantly reductive or oxidative) is strictly associated with the steroid receptor status of cells. We explored intra-tissue concentrations and profiles of estrogens in a set of human breast tumors as compared to normal mammary tissues, also in relation to their estrogen receptor s…

Receptor StatusTime FactorsIntratumor estrogenCatecholsBreast cancer; Intratumor estrogens; Sex steroids; Adsorption; Androstenedione; Animals; Breast Neoplasms; Catalysis; Catechols; Cell Line Tumor; Chromatography High Pressure Liquid; Disease Progression; Estradiol; Estrogens; Humans; In Vitro Techniques; Ions; Kinetics; Models Biological; Neoplasms; Steroids; Time Factors; Biochemistry Genetics and Molecular Biology (all)Sex steroidmedicine.disease_causeEndometriumCatalysiBreast cancerNeoplasmsEstrogen Receptor StatusChromatography High Pressure LiquidEstradiolGeneral NeuroscienceSex hormone receptormedicine.anatomical_structureDisease ProgressionSteroidsBreast NeoplasmHumanmedicine.medical_specialtyTime FactorBreast NeoplasmsIn Vitro TechniquesBiologyModels BiologicalCatalysisGeneral Biochemistry Genetics and Molecular BiologyBreast cancerHistory and Philosophy of ScienceCell Line TumorInternal medicinemedicineAnimalsHumansIonSteroidKineticIonsBiochemistry Genetics and Molecular Biology (all)AnimalIn Vitro TechniqueAndrostenedioneCancerEstrogensmedicine.diseaseEstrogenKineticsEndocrinologySex steroidCatecholNeoplasmAdsorptionCarcinogenesis
researchProduct